Compare Citius Pharmaceuticals Inc (CTXR) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ferrari NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Ferrari NV trades at $389.24 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 4944.9× Citius Pharmaceuticals Inc's market cap, and Ferrari NV pays a 1.09% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Ferrari NV for 126 Days on average.
| CTXR | RACE | |
|---|---|---|
Market Cap | $13.62M | $67.35B |
Volume | 132,438 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $436.54 |
52-Week Low | $0.48 | $314.63 |
Typical Hold Time | 17 Days | 126 Days |
Enterprise Value | $3.79M | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Ferrari (RACE) trades at $388.77, up 0.62% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15 billion in 2025, and net income margin remains robust at 22.25%. The company is executing a share buyback program and expanding partnerships, such as with Rakuten effective 2027.
The outlook is positive given analyst consensus of $462.75 price target and 73.69% buy ratings. Risks include high valuation multiples and exposure to economic cycles. Institutional interest is rising, but technical indicators suggest near-term resistance at $390.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
